Pulled from Cardiovascular Business and ACC / JACC — refreshed hourly.
After months of consideration, CMS has officially signed off on major changes to its TAVR policies. The treatment of asymptomatic patients is now covered by Medicare, for example, and fewer reporting requirements are in
Cardiovascular Business
The inflammatory biomarker interleukin (IL)-6 identified residual inflammatory risk of incident heart failure (HF) in patients with type 2 diabetes (T2D) and overweight/obesity, particularly among those with no history o
ACC / JACC
The Cardiac PET Alliance said it wants to advance education, research and advocacy surrounding cardiac PET imaging.
Despite declines in disability-adjusted life years (DALYs) and mortality rates from myocarditis globally from 1990 to 2023, its incidence and prevalence remained stable, suggesting improvements in disease outcomes over t
A new study of more than 11,000 patients suggests that darkness is necessary for the heart to function at full strength. “Light pollution has emerged as a new risk factor for cardiovascular disease," one researcher expla
If a malfunction does occur, Stryker warned, it could impact the device's effectiveness. No adverse events have been reported at this time.
A novel left atrium (LA) staging framework proposed by Jaehyun Lim, MD, PhD, et al., was independently associated with a significant, stepwise increase in risk of new-onset atrial fibrillation (NOAF) in patients with hyp
In this episode, Dr. Ami Bhatt speaks with Dr. Sneha Jain about evaluating and monitoring artificial intelligence tools for clinical practice.
Heart failure is the most expensive heart condition treated in hospitals, a Healthcare Cost and Utilization Project report found. The report, published February 2026, used 2022 data from the Agency for Healthcare Researc
Becker's Cardiology Review
The Emboliner Embolic Protection System held its own in a recent head-to-head comparison with Boston Scientific’s Sentinel Cerebral Protection System. With FDA approval now secured, Emboline hopes to launch the device in
As cardiovascular subspecialties continue to grow, deficiencies have been exposed in the current training model. A recent State-of-the-Art Review published in JACC: Advances reviews the current training model and how it
Miami-based Nicklaus Children’s Hospital Heart Institute is one of the first in the U.S. to successfully perform a Fontan procedure using a transcatheter-based approach on a child. The two-year-old child was born with a
The ALL-RISE (Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment) trial results demonstrated that, among patients with intermediate coronary stenoses undergoing invasive angiography, an angiography-d
The Advanced Research Projects Agency for Health has awarded contracts to six teams to build the first FDA-authorized agentic AI system for cardiovascular care. ARPA-H announced the selections Sept. 9 under its Agentic A
The American Medical Association released its 2027 Current Procedural Terminology (CPT) code set Sept. 9, an update that adds 299 codes and continues to build out billing for clinical AI. The set takes effect Jan. 1 and
A majority of TAVR patients also present with a history of heart failure. New research suggests many of them are not being prescribed the medications they need.
Questions about menopause, oral contraceptive use and hormone replacement therapy should all be part of the conversation when evaluating a woman's cardiovascular health.
The end-to-end platform provides ultrasound imaging courtesy of a 360° catheter that creates real-time 2D and 3D maps of the patient’s heart. It also offers advanced visualization and navigation capabilities.
Management of intermediate-risk pulmonary embolism (PE) remains one of the most challenging areas in venous thromboembolism care. These patients are hemodynamically stable but have right ventricular (RV) dysfunction and
In this week’s View, Dr. Eagle looks at some of the important trials presented at this year’s European Society of Cardiology (ESC) Congress.
The new ASNC document includes detailed SPECT- and PET-specific protocols, patient preparation recommendations and a fresh look at safety.
"I want to be safe, I want to get the vessel open and I don’t want to spend a long time doing it," cardiologist William C. Dixon, MD, explains. "IVL helps me achieve all of those things.”
Pelacarsen, an investigational heart drug developed by Novartis, did successfully reduce Lp(a) levels in high-risk heart patients. However, it was unable to reduce the risk of major adverse cardiovascular events among th
The FDA-cleared device was built specifically with the tricuspid valve in mind.
